Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.
about
A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivoEnhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for CancerEpigenetic Guardian: A Review of the DNA Methyltransferase DNMT3A in Acute Myeloid Leukaemia and Clonal Haematopoiesis.Acid ceramidase is upregulated in AML and represents a novel therapeutic target.Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines.Comprehensive Analysis of MILE Gene Expression Data Set Advances Discovery of Leukaemia Type and Subtype Biomarkers.Characterization of Common Chromosomal Translocations and Their Frequencies in Acute Myeloid Leukemia Patients of Northwest Iran.Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activityComprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.Distress in patients with acute leukemia: a concept analysis.Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemiaNew agents for acute myeloid leukemia: is it time for targeted therapies?Blastic leukaemias (AML): a biologist's view.Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?Genomic characterization of acute leukemias.Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date.Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines.Immune evasion by oncogenic proteins of acute myeloid leukemia.Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expressionAzacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.Peptide microarray profiling identifies phospholipase C gamma 1 (PLC-γ1) as a potential target for t(8;21) AML.Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk GroupsThe microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells.HLA-B*40 allele plays a role in the development of acute leukemia in Mexican population: a case-control study.Prognosis of patients with t(8;16)(p11;p13) acute myeloid leukemia.MGMT promoter methylation as a potential prognostic marker for acute leukemia.The Tumor Suppressor, P53, Decreases the Metal Transporter, ZIP14.Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.Novel IRF-1 Mutations in a Small Cohort of Leukaemia Patients From Saudi ArabiaCDK9 inhibitors in acute myeloid leukemia.Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells.Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.Drug discovery. Tying up a transcription factor.Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.Expression of aberrant antigens in hematological malignancies: A single center experience.Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).Data integration by multi-tuning parameter elastic net regressionAbnormal microRNA expression in the course of hematological malignancies
P2860
Q27684428-E4EA4E09-6C11-4ECC-9778-B234DD5B631EQ29147555-EFE29BA3-BD79-488B-8998-E563625245ADQ30235316-3678C6E1-F02E-4CC6-A9CE-D7CCD49A9FA7Q30275460-2B76C69B-80EB-44FB-93E0-DEE1F8DCB246Q30300790-A592F5C4-0704-4701-9BB6-32F47C71B2A2Q30301001-78CFAF39-11A7-41CC-9772-392162201184Q36311655-285565AA-1EE9-4C70-BD6D-78FFAFE1BD72Q36761201-D32BAE0A-08F3-4653-B347-3B95DC271E25Q36862902-85297766-7DB2-4FE6-A353-615F0FD34E4BQ36873301-2FC03483-C387-4DDF-B38A-755E0FB71A22Q37188719-EA642C36-DA41-48A8-A410-579B0CA18986Q37225379-9C46F5A9-DA1B-4CBC-ABDB-F1F63FD9367AQ37973135-B0F1E214-4B01-4644-B2B1-B9A5A1DA19F5Q38026774-13BCFD7B-48DB-4FBE-AD3F-9A5C5773DDEDQ38091393-8393D9CC-8C29-45C7-AAB5-0DD73B18D133Q38223490-4511DC2C-00DE-45CF-949F-0966C6902183Q38270780-D4F52258-2F17-433C-AF5C-C68781DFBFCEQ38426552-3C74E21A-69EF-4FB1-8F59-6930F36FCD7AQ38683676-70CEAE8C-1773-4F18-9BAD-34D33D8BB939Q38880553-01659D5E-519F-48C1-B765-ACC76495D9F2Q38983626-D3CAF72A-5F65-4BB5-AE4C-E4FEDC0D0E54Q41004145-437FE08B-5D8F-424D-A898-E9622100DCC1Q41815540-8E7A05C6-710E-4F92-949F-91F406E0E56FQ41983363-D5F5257C-0AFA-4AAA-81F4-A4D5843D3DC1Q42063012-7C186A34-DB5B-4C40-A3E3-95E28611431AQ42824980-371AA22B-EAD0-421A-A55C-7724058752A5Q43574379-72B88214-72E3-4552-A838-11241D1A19D4Q47138733-5E368B89-43D5-4590-9E05-DF709C31F081Q47182725-0F3F22D4-B52F-474D-8EE8-0ADC6C4B8F6AQ49833698-274FBC6A-C19B-48D4-A416-2E0496ED9923Q50088467-96152592-07B6-471C-81CE-C08A60B11C8CQ50318294-662AF6FB-6823-498D-9D44-2A3728CC3089Q51089294-9AC7298E-7CAD-4D62-AA11-FC323FF45437Q51205193-D2D96D03-7EC5-43FE-804C-06212ED3140CQ53314600-7B1E2E0D-6E26-4C2C-9616-E6677F765DEAQ53590608-B8C5C94A-C92E-421D-BA06-0CF1BB82B067Q54967676-8817B392-4B67-48C9-AD16-7228127ADD99Q55283900-BC98654B-3191-4EE6-A3AE-2890C135FB11Q57282822-D262E872-15FF-47AB-ABCD-4C0838689316Q57817341-19EACD8F-38B8-461B-8A78-0B03CC051813
P2860
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.
@ast
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.
@en
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.
@nl
type
label
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.
@ast
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.
@en
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.
@nl
prefLabel
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.
@ast
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.
@en
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.
@nl
P2860
P356
P1433
P1476
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.
@en
P2093
C Chandra Kumar
P2860
P304
P356
10.1177/1947601911408076
P577
2011-02-01T00:00:00Z